AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq

AbbVie raised its annual profit forecast on Wednesday after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings.

Sign up for Reuters newsletters Reuters Business Reuters Business

AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq

Garmin raises full-year guidance, results beat amid unabated demand

China's BYD posts 11.5% rise in Q3 net profit

GE HealthCare beats Q3 profit estimates on U.S. demand for medical devices

BYD appoints former Stellantis UK chief Davino to push European expansion

UK Budget 2024 Live: Tax hikes and health service funding trailed for 'rebuild Britain' plan

Digital ad sellers jump as Google, Reddit and Snap earnings indicate sturdy demand

China tells carmakers to pause investment in EU countries backing EV tariffs, sources say

Kraft Heinz trims annual forecasts as high prices hinder demand recovery

Embraer's Eve gets $50 million Citi loan to fund 'flying car' development

Sponsors are not involved in the creation of newsletters or other Reuters news content. Advertise in this newsletter or on Reuters.com Reuters Business is sent every weekday. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here. Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here. Terms & Conditions and Privacy Statement

© 2024 Thomson Reuters. All rights reserved. 3 Times Square, New York, NY 10036